ArticlePharmaceuticals (Basel, Switzerland)2023

Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome.

Andrei A Savchenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.